FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval

Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.

from Health and Science https://ift.tt/6kFXrlf
https://ift.tt/b3SmKk4
https://ift.tt/RKcnyQu